Successful treatment of immunoglobulin D myeloma by bortezomib and dexamethasone therapy

2Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Immunoglobulin D (IgD) myeloma is a rare subtype and it is widely accepted as an aggressive disease. Here, we report a 66-year-old woman with IgD myeloma who had anemia, lumbago, multiple osteolytic lesions and hypercalcemia. The patient refused a blood transfusion because of her beliefs, so we administered bortezomib and dexamethasone (BD) after high-dose dexamethasone therapy. Marked improvement of anemia and elevated serum alkaline phosphatase levels was recognized. After 5 cycles of BD therapy, the patient achieved a stringent complete response according to International Myeloma Working Group Response Criteria. BD therapy might be a feasible and useful treatment option for IgD myeloma. © 2011 The Japanese Society of Internal Medicine.

Cite

CITATION STYLE

APA

Sekiguchi, N., Takezako, N., Nagata, A., Wagatsuma, M., Noto, S., Yamada, K., & Miwa, A. (2011). Successful treatment of immunoglobulin D myeloma by bortezomib and dexamethasone therapy. Internal Medicine, 50(21), 2653–2657. https://doi.org/10.2169/internalmedicine.50.5977

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free